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Abstract
Insulin resistance is one of the major aggravating factors for metabolic syndrome. There are many methods
available for estimation of insulin resistance which range from complex techniques down to simple indices. For all
methods of assessing insulin resistance it is essential that their validity and reliability is established before using
them as investigations. The reference techniques of hyperinsulinaemic euglycaemic clamp and its alternative the
frequently sampled intravenous glucose tolerance test are the most reliable methods available for estimating
insulin resistance. However, many simple methods, from which indices can be derived, have been assessed and
validated e.g. homeostasis model assessment (HOMA), quantitative insulin sensitivity check index (QUICKI). Given
the increasing number of simple indices of IR it may be difficult for clinicians and researchers to select the most
appropriate index for their studies. This review therefore provides guidelines and advices which must be
considered before proceeding with a study.
Background
An index of insulin resistance (IR) can be defined as a
quantitative measurement of the biological effect of
endogenous or exogenous insulin in relation to the ambi-
ent blood glucose level. IR is considered to be an inde-
pendent risk factor for the development of metabolic
syndrome and diabetes. Predisposition to IR is multi-fac-
torial, with strong genetic and environmental influences.
Over recent years there has been widespread scientific
interest in this topic as it has become apparent that IR
develops early in the pathological process leading to dia-
betes. Many studies have shown that it may predate the
onset of the diabetes by 10-20 years [1]. Quantitative
assessment of IR may therefore be useful for detecting its
presence and assessing its severity, particularly in subjects
who have not as yet developed abnormal glucose toler-
ance or diabetes. Although the presence of IR can be
inferred from clinical findings it is not currently common
practice to quantitate it in clinical contexts. Its quantita-
tion is largely confined to research studies.
In a previous literature review [2] we classified methods
of assessing IR into three main categories viz dynamic
tests, simple indices and biochemical markers. In the
dynamic tests such as the hyperinsulinaemic euglycaemic
clamp (HEC) and its alternative technique the frequently
sampled intravenous glucose tolerance (FSIVGTT) blood
samples are collected serially. These are considered refer-
ence techniques. Relatively simple, non-invasive alterna-
tives to the clamp technique have been proposed, such as
homeostasis model assessment (HOMA). In addition it
has been observed that measurement of individual bio-
chemical protein markers such as insulin-like growth fac-
tor binding protein-1 (IGFBP-1) can provide useful
information about the status of IR [3-5].
Previously studies have discussed the available methods
for assessing IR including their applications and limita-
tions [6,7] while other suggested some general require-
ments for an ideal method for measuring IR [8,9].
Faced with the wide array of indices available, it may be
difficult for investigators to decide which is the most sui-
table for a particular purpose. However, no previous sin-
gle publication has discussed the various factors that
need to be considered in method selection. In this review
we have collated available information on these factors in
an effort to guide investigators in their choice of method.
General considerations for choosing the appropriate
technique prior quantitating insulin resistance
Investigators planning a study in which IR will be quan-
titated should in the first instance be clear about the
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type of study to be undertaken as this is the principle
factor in determining the choice of method. The differ-
ent types of study described in the literature and broad
choice of method are summarised in Figure 1. The
investigator should have prior knowledge of the available
methods for assessing IR, their limitations and how to
prepare subjects prior to investigation.
In making a decision, consideration should be given to
the additional information required beyond the determi-
nation of IR. Some methods, particularly reference tech-
niques, permit estimation of additional parameters of
interest. Furthermore, some techniques provide an esti-
mate of hepatic or peripheral IR or both. The investigator
needs to consider whether the IR index is the primary
endpoint of the study, such as would be the case in a
study comparing IR between two populations, or of sec-
ondary interest. In selecting methodology there will be
obvious logistical factors to consider. Below we consider
in detail the different methods available for assessing IR
and factors which investigators need to consider.
Reference techniques
The HEC should be the test of first choice in studies
where IR is of primary interest [10]. It is a steady-state
technique which requires a constant insulin infusion.
Clearly this is unphysiological thus the HEC is not
appropriate when an estimation of insulin action and
glucose dynamics under normal physiological conditions
is required.
Owing to the complexity of the HEC, the FSIVGTT
may be preferred as an alternative option and, as such,
can be considered the ‘silver’ standard [11]. The main
FSIVGTT techniques available are the standard (classi-
cal) technique and the more modern insulin-modified
version. Simplified short sampling protocols have been
described for ease of studying large numbers of subjects
[12]. Unlike the HEC, the FSIVGTT relies on dynamic
glucose and insulin data obtained before and following
an intravenous glucose bolus. It therefore measures IR
indirectly. All FSIVGTT techniques require minimal
model analysis in order to derive the insulin sensitivity
index, Si. This can only be done using software packages
such as MINMOD. Many different software packages
are available but do yield slightly different results. Inves-
tigators should endeavour to use the most modern ver-
sion. In addition to determining Si, the differential
equations used by the MINMOD program can be uti-
lised to estimate many other parameters of interest e.g.
Figure 1 Different types of insulin resistance studies.
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glucose effectiveness (Sg), b-cell activity (b-cell), acute
insulin response (AIR), disposition index (DI) and area
under the curve (AUC). For investigators who are inter-
ested in these parameters the FSIVGTT will be the test
of choice. However, it should be anticipated that for
some subjects it may not possible to derive the various
parameters from the available data. This is a common
limitation of the technique encountered by authors,
including ourselves, which should be taken into account
when planning the number of study subjects to be
recruited.
For investigators interested in assessing hepatic glu-
cose production (HGP) and IR, stable isotopes of glu-
cose can be used in combination with clamp or
FSIVGTT techniques. For further details on this topic
readers are directed to an appropriate reference [13,14].
Other dynamic techniques such as the insulin tolerance
test (ITT) and continuous infusion of glucose with
model assessment (CIGMA) have not been widely
benchmarked and only a few groups have used them in
their studies [15-17]. We will not therefore discuss them
further here.
Number of subjects
The number of subjects involved in a study is an impor-
tant determinant of the feasibility of a given technique
(Figure 2). It is well recognised that the reference techni-
ques are generally unsuitable for epidemiological studies
involving large numbers of subjects. However, there have
Figure 2 Protocol for selection the most appropriate technique for assessment of insulin resistance prior to commencement of a
study.* This option is preferred. Key: FSIVGTT, frequently sampled intravenous glucose tolerance test; GTT, glucose tolerance test; HOMA,
homeostasis model assessment; IGFBP-1, insulin-like growth factor binding protein-1; ISI-gly, insulin sensitivity index of glycaemia; ITT, insulin
tolerance test; CIGM, continuous infusion of glucose with model assessment; QUICKI, quantitative insulin sensitivity check index; SHBG, sex
hormone binding protein.
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been exceptions and, in principle, there is no reason why
a reference technique should not be used in an epidemio-
logical study provided sufficient resources are available.
In the IR atherosclerosis study a large number of subjects
(n = 1,625) was used to examine the association between
Si derived from insulin-modified FSIVGTT and other
cardiovascular risk factors [18]. In general however, refer-
ence techniques have been confined to studies with rela-
tively low numbers of subjects, especially when it is a
pilot study investigating a new treatment modality or
where a novel method is being validated [5,19].
Glycaemic status of subjects
Knowledge of the subjects’ glycaemic status influences
the choice of method. Where subjects with diabetes are
to be studied, the HEC or insulin-modified FSIVGTT
should be used. The classical FSIVGTT relies solely on
the endogenous insulin response which, in diabetic sub-
jects, may be insufficient to permit determination of Si.
In addition, short protocol FSIVGTTs are best avoided
in subjects with diabetes owing to poorer correlation of
Si with the gold standard in these subjects. Clearly the
glycaemic status of study subjects should be known by
the investigator beforehand.
Budget
Budgetary constraints will clearly impact on the choice
of the method. Where sufficient funds are available, the
HEC reference technique is first choice but if this is not
possible then the FSIVGTT would be recommended.
However, it should be noted these methods cost 20-30
times more than the simple indices. Both the HEC and
FSIVGTT require a dedicated member of staff with the
necessary expertise. In the authors’ experience it is
desirable, in addition, to have a second member of staff
available with expertise in the technique during atten-
dance of study subjects, a factor worth considering in
planning. Clearly this must be taken into account in
budgetary considerations as staffing is likely to be the
most significant contributor to the cost of the research.
Materials and equipment
The availability of appropriate technical expertise and
materials must be considered if a reference technique is
to be used. Essentially these techniques should be
undertaken in a fully equipped clinical investigation unit
in the presence of a suitably trained member of staff (e.
g. a nurse) able to manage any complications which may
arise. A field study involving subjects who are unable to
travel to the research centre would clearly preclude the
use of a reference technique and demand use of simple
technique on a single sample which could be processed
and transported appropriately to the laboratory.
Experience with data analysis is another important
factor to consider. If for example a software package
such as MINMOD is to be used in conjunction with the
FSIVGTT, for sophisticated data analysis, the operator
should have the necessary skills for analysing the data
and have access to support [20]. Both the HEC and
FSIVGTT require cannulation of subjects, unlike the
simple IR indices which only require straightforward
venesection. The subjects’ veins therefore need to be of
sufficient quality if they are to be included and an
operator must be present who possesses the necessary
expertise.
Previous studies
Before utilising a reference technique in a study, it is
advisable to share information with those with previous
expertise in the technique so that potential difficulties
and hazards, such as the risk of insulin-induced hypo-
glycaemia, can be identified. This will also enable the
researcher to ascertain necessary details such as the pro-
tocol for use, possible application, pitfalls and
limitations.
Simple indices of insulin resistance
A simple index of IR can be defined as an index which
does not require the intravenous administration of exo-
genous insulin or glucose. It can be estimated either
from a fasting specimen alone or fasting specimen along
with other blood samples taken following an oral glu-
cose load. Simple indices, unlike dynamic techniques, do
not demand steady state conditions. Owing to their ease
of application and convenience to subjects, simple
indices are the most commonly used tools for estimating
IR. Therefore, it is important to be aware whether a
simple index of IR can or cannot be utilised in a given
study. Criteria for use of simple indices of IR in a study
are summarised in Table 1. Whilst these are attractive
in terms of their ease of use and inexpensive nature,
investigators need to be aware of their limitations.
1. Oral glucose tolerance test (GTT)-derived indices
Mathematical formulae have been derived which repre-
sent the kinetics of insulin and glucose levels at different
time intervals before and after administration of a 75 g
oral glucose load during an oral glucose tolerance test
(GTT). Several IR indices have been derived from two
(0 and 120 min) to four (0, 30, 60 and 120 minutes)
samples of insulin and glucose taken in the context of a
GTT (Table 2). More GTT-derived indices have been
described which are summarised by Monzillo et al., [7]
and Matsuda et al., [21]. Most but not all studies indi-
cate that these indices are more reliable than other sim-
ple fasting indices of IR as their correlation with
reference techniques was stronger than that of fasting
indices [4,9,21-24]. This is to be expected as GTT-
derived indices take post-load glucose-insulin interaction
into account. Whenever the dynamic techniques cannot
be utilised in a study, simple GTT-derived indices
should therefore be next in line for quantitation of IR.
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Physiological response
A criticism of the gold standard test is that the indices
derived are not measured under physiological circum-
stances. When the investigator wishes to use an index
that reflects the physiological insulin response to a glu-
cose load then it is appropriate to use one derived from
parameters measured during a GTT. These surrogate
indices are derived from a dynamic response which gen-
erally incorporates both peripheral and hepatic IR. An
advantage of the GTT-derived indices over those
derived from fasting insulin and glucose alone is that
they can detect subtle disturbances in glucose metabo-
lism not apparent from the latter [25,26]. Simple indices
based solely on fasting measurements cannot always
reliably estimate IR, since it is possible for subjects to be
significantly insulin resistant without having fasting
hyperinsulinaemia. Furthermore, some individuals may
be euglycaemic when fasting but hyperglycaemic and
hyperinsulinaemic two hours following a 75 g oral glu-
cose load. It is recognised that even in healthy indivi-
duals with hepatic IR, regular diet, exercise or glucose
lowering medications can restore both fasting glucose
and insulin levels to well within normal ranges [27,28].
In the authors’ experience, the larger the number of spe-
cimens collected from an individual, the more accurately
the derived parameters are likely to reflect insulin sensi-
tivity [29]. This is because the biological variation of
insulin and glucose levels has less impact on the value
of the parameter when it is derived from a larger quan-
tity of data.
It is noteworthy that the early glucose response during
a GTT can be considered an index of hepatic IR, while
the drop in glucose levels from peak to nadir estimates
peripheral IR predominantly of skeletal muscle with a
smaller contribution from adipose tissue [30]. A poten-
tial limitation of the GTT is poor reproducibility [31].
This arises from intra-individual variation in glucose
handling both pre- and post-absorption. This problem
can be reduced by repetition of the test on two or three
occasions at short intervals and taking the mean of the
results, if the investigator considers this feasible.
2. Fasting sample-derived indices
IR indices can be derived from fasting samples using
mathematical formulae representing the kinetics of fast-
ing insulin with or without glucose measurement (Table
2). These are the most commonly used indices of IR.
The reasons for this wide application are their simpli-
city, cost-effectiveness and practicality as only one fast-
ing sample is required and there is no requirement for
Table 1 Criteria for studies in which simple indices of insulin resistance may be used.
Study objectives
1. Large clinical practice and epidemiological investigations [70].
2. Where the assessment of direct IR is not required.
3. Where the outcome of IR is of secondary interest [71].
4. Where the requirements of reference techniques are not available e.g equipments, trained staff, enough budget.
5. Where a new simple index is under evaluation [72,73].
6. Investigating validity and pitfalls of simple indices in specific clinical conditions [41,57].
References have been provided as a study example:
Table 2 Formulae for the most commonly used simple indices of insulin resistance derived from fasting specimens
and other specimens taken in the context of an oral glucose tolerance test (GTT).
Index Formula Reference
GTT derived indices:
ISI-gly 2/[(INSp × GLYp)] + 1 [74]
ISI (composite) 1000/√{[fasting glucose (mg/dL) × fasting insulin (μU/mL)] × [mean glucose × mean insulin]} [21]
Fasting sample indices:
HOMA-IR Fasting glucose (mmol/L) ×fasting insulin (mU/L)/22.5 [36]
HOMA2-S HOMA2 calculator version 2.2 [37]
FGIR Fasting glucose (mg/dL)/Fasting insulin (mU/L) [58]
Raynaud 40/Fasting insulin (mU/L) [33]
Reciprocal insulin 1/fasting insulin (mU/L) [34]
QUICKI 1/[log fasting insulin (mU/L) + log fasting glucose (mg/dL)] [46]
FGIR Fasting glucose (mg/dL)/Fasting insulin (mU/L) [58]
Key: GTT, oral glucose tolerance test; HOMA-IR, homeostasis model assessment insulin resistance; QUICKI, quantitative insulin sensitivity check index; FGIR, fasting
glucose insulin ratio; ISI (composite), an index of whole-body insulin sensitivity; ISI-gly, insulin sensitivity glycemic index; INSp, insulinemic area; GLYp, glycemic
area.
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administration of a glucose load. The main problems for
the investigator are understanding the information that
each index provides and choosing one from the large
number available. The investigator should be mindful of
the fact that these indices vary widely in their reliability
[32]. Not all have been rigorously validated against the
gold standard. The following points therefore need to be
considered before selecting any fasting sample-derived
index.
Parameters involved in the formula
Many of the formulae for indices derived from fasting
specimens are simple using the fasting insulin level
alone. An example of this is the Raynaud index which
describes the best-fit relationship between fasting insulin
and Si [33]. Another simple index is the reciprocal of
the fasting insulin level (1/insulin) [34]. In spite of the
modification of the original data by such formulae, these
indices still rely solely on the insulin level and conse-
quently suffer from the same limitations as the fasting
insulin level alone [2]. Formulae which incorporate at
least the two main parameters viz insulin and glucose,
are preferable over those utilising insulin alone. Such
formulae represent the exchangeable kinetics between
both parameters which ultimately estimate IR. Other
formulae have been reported which incorporate more
than two parameters for example the lipid-parameter
based formula [35]:
Lipid−based index = 12×[2.5×(HDL−C/Total cholesterol)−NEFA]−Fasting insulin
(HDL-C, high density lipoprotein cholesterol; NEFA,
non-esterified fatty acids)
Indices which incorporate more than one parameter
have high validity in predicting IR as demonstrated by
their close association with reference test-derived indices
of IR.
Upgraded and modified formulae
Simple IR indices have undergone regular modification
by researchers in an effort to improve their applicability.
Upgraded formulae have been observed to be more clo-
sely associated with reference test-derived indices and
consequently more reliable and accurate. For example,
the original HOMA equation (HOMA-IR) has been
modified to HOMA2 to allow for increased plasma insu-
lin and glucose levels [36,37].
Another means by which equations have been
upgraded is incorporating additional parameters into
their formulae. For example the fasting non-esterified
fatty acid (NEFA) concentration when incorporated into
the regular formula of QUICKI (quantitative insulin sen-
sitivity check index) improves the estimation of IR as
the modification enhances its correlation with the
clamp-based index of insulin sensitivity and its discrimi-
natory power [38,39]. Another example is the use of
fasting C-peptide as a substitute for insulin in determin-
ing HOMA-IR which can be applied to subjects with
insulin-treated diabetes [40]. Researchers using a simple
index of IR are advised to use the most up-to-date ver-
sion in order to obtain the strongest correlation with
reference methods.
Mathematical considerations
Due to the simple mathematical nature of some fasting
sample-derived indices, there is the potential for their
output to be misinterpreted in some subjects particu-
larly in those with type 2 diabetes where their levels
may be paradoxically and erroneously increased e.g. fast-
ing glucose to insulin ratio (FGIR), 1/fasting insulin.
This is due to low insulin secretion by pancreatic b-cells
[41].
One feature of both the simple and reference method-
derived indices of IR is that their values tend to be posi-
tively skewed yielding a hyperbolic curve when non-
transformed data is examined. They become normally
distributed following log-transformation. Previous stu-
dies have shown an improvement in their correlation
with the reference techniques after log-transformation
[4,42-45]. The QUICKI index for example is similar to
HOMA, except that it interprets the data by taking both
logarithms and the reciprocal of the fasting glucose-
insulin product. The log-transformation included in the
formula of QUICKI results in greater accuracy than
HOMA in calculations over a broad range of insulin
sensitivity and in stronger correlation with the HEC (r =
0.78, p < 2 × 10-12) [46,47]. Similarly, log or ln transfor-
mation of all simple indices of IR results in a stronger
association with reference techniques and consequently
an improvement in IR estimation. However, the degree
of improvement reported varies between indices [4,46].
Biological variation
Recent studies have indicated that the biological varia-
tion of insulin levels and fasting sample-derived indices
of IR are greatly influenced by the degree of glucose tol-
erance and also by IR-modifying medications [48-50].
Owing to biological variation in fasting insulin levels,
values for fasting sample-derived indices are more reli-
able in subjects with normal glucose tolerance than in
individuals with type 2 diabetes. These factors should be
borne in mind by researchers carrying out studies which
involve repetition of levels at various time intervals. It
may be advisable to confirm the glycaemic status by
means of a GTT particularly if a long time interval is
involved such as during a prospective study, as the gly-
caemic status may change over the course of the study.
Researchers should also be aware that the values for
indices which utilise multiple parameters will reflect the
biological and analytical variation of each individual
parameter. The result obtained for any index is only as
good as the data entered.
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Multiple simple indices
Where there is uncertainty as to which simple index is
most suitable in a study, more than one can be used
simultaneously e.g. HOMA-IR, QUICKI, etc. This may
help to minimise the effect of limitations of some
indices and increase the likelihood of obtaining mean-
ingful differences between categories of subjects under
investigation [26,42,51]. In the authors’ experience, the
results of different simple indices are not always in line
with each other. It is therefore wise to use more than
one index in a given study in order to avoid reaching
erroneous conclusions.
Insulin assay
The nature of the insulin assay to be used must be
taken into consideration before commencing any study
of IR, not only for those using simple indices. Currently
all insulin assays are standardised using the same refer-
ence preparation but values obtained using different
insulin assay kits may show significant bias. This may be
due to variable specificity, different calibration set-up in
kits or different factors used to convert between units
(from mIU/L to pmol/L) which vary from 6.0 to 7.46
[52]. Insulin represents the main parameter involved in
the estimation of any simple index estimation. Manley
et al., found that the distribution of HOMA2-IR esti-
mates for different insulin assay (11 assays) varied by up
to twofold, depending on which insulin assay was used
[53]. Bias in results obtained by different insulin assays
may contribute to the differences in reported cut-off
values for IR in different populations [54,55]. In view of
the above, it is highly advisable that, in any given study,
one source of insulin assay is used throughout which
has high performance criteria (i.e. company, antibodies).
In addition, the same lot number of the assay products
should be used if possible. This is particularly important
in large prospective studies.
Limitations of simple indices
Indices derived from fasting samples can be unreliable
when applied to certain groups of subjects viz the
elderly and those with uncontrolled diabetes or type 1
diabetes [46,56,57]. The measured insulin level will not
accurately reflect the degree of IR in these individuals as
the b-cells are unable to secrete sufficient insulin to
overcome existing IR. Indices derived from fasting sam-
ples are therefore more reliable when applied to indivi-
duals with sufficient insulin secretion. For example
FGIR has been observed to be reliable in subjects with
polycystic ovary syndrome (PCOS) except those who
also have type 2 diabetes [41,58]. As is the case with the
reference techniques, it is therefore advisable, when
using simple indices, that the subject’s glycaemic status
is classified beforehand by means of a GTT and WHO
criteria, even where post-load values are not required
for determination of the index itself.
Simple indices based on fasting levels of glucose and
insulin (e.g. HOMA-IR and QUICKI) assess hepatic IR
more than peripheral insulin sensitivity. This has been
demonstrated by the strong relationship observed
between simple indices and the reference parameter of
hepatic IR obtained by Hoffman et al., utilising
FSIVGTT technique [59]. Hepatic IR is considered the
major determinant of fasting hyperglycaemia and as
such is the major factor contributing to the pre-diabetic
state, impaired fasting glucose [18,19]. In most circum-
stances peripheral tissue IR develops later than hepatic
IR [19]. This is an important limitation of fasting simple
indices. Whilst hepatic and peripheral IR correlate with
each other the relative contribution of each varies
between individuals.
3. Biochemical markers of IR
The concentration of a given protein obtained from a
fasting blood sample is potentially a more convenient
means of assessing IR than measuring glucose and insu-
lin together. Many possible biochemical markers were
discussed in our previous review [2].
Degree of insulin resistance
Other than the fasting insulin level itself, initial studies
have indicated that proteins which are either directly or
indirectly insulin-regulated are more reliable as markers
of IR than insulin independent protein markers
[3,5,60,61]. In individuals with normal glucose tolerance
the application of these biochemical markers is very reli-
able and convenient as they have been observed to be
highly associated with IR parameters determined by
reference techniques. However, they have been noted to
be less-reliable in subjects with more marked degrees of
IR resulting in an abnormal glucose tolerance [4,5,62].
This observation may be due to the presence of hepatic
IR and consequently irregular secretion of these markers
by hepatocytes as liver is considered to be the main
source of most of these biochemical markers.
Ratio between different markers
The ratio of biochemical markers other than insulin and
glucose may be another option for a simple and efficient
marker of IR. For example, the ratios of leptin to adipo-
nectin or between triglycerides and high density lipopro-
tein cholesterol can be considered useful markers of IR
[63-65]. Low triglyceride levels are usually associated
with increased insulin sensitivity but it appears that the
relationship between triglycerides and insulin sensitivity
differs between races, African-Americans for example
having lower triglyceride levels in spite of increased
insulin resistance [66]. Therefore, as with all biochem-
ical markers, the results of these indices should not be
interpreted in isolation but in the context of other find-
ings including anthropometric measurements such as
body mass index (BMI) and waist circumference and
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biochemical measurements. Age, gender, race etc. should
be considered also.
Biological variation for different markers
The issue of biological variation as discussed above in
relation to fasting indices, also applies to single bio-
chemical markers of IR. Jaygobal et al., previously inves-
tigated the biological variation of sex hormone binding
globulin (SHBG) as a biochemical marker of IR [67] and
found that a second level must rise or fall by > 14.5% to
be considered significantly different from the first in
subjects with type 2 diabetes. Similarly, we assessed the
biological variation of serum IGFBP-1 in individuals
with different degrees of glucose tolerance [68]. Our
study showed that biological variation of IGFBP-1 is
lowest in normal glucose tolerant individuals and
increased with deteriorating glucose tolerance. There-
fore, biological variation should be considered whenever
biochemical markers, influenced directly or indirectly by
insulin, are utilised to assess IR. Generally, biological
variation for most of the analytes and proteins including
other biochemical markers can be retrieved from the
database using the following website (http://www.west-
gard.com/biodatabase1.htm) [69].
Conclusions
A wide variety of methods are available for assessing IR
including reference techniques and simple indices. In
planning studies on IR and selecting a suitable index, a
number of important factors need to be considered by
investigators, the principle one being the nature of the
study to be undertaken. Where possible the HEC, as the
most accurate technique available, remains the first
choice but simpler and inexpensive methods may be
appropriate provided the investigator is aware of their
limitations.
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